Mobile Site ›
Print Friendly View

Test ID: HL15O    
HLA-B 1502 Genotype, Carbamazepine Hypersensitivity, Saliva

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Conditional

Useful For Suggests clinical disorders or settings where the test may be helpful

Identifying individuals of Asian ancestry who are at risk of developing Stevens-Johnson syndrome and toxic epidermal necrolysis when administered carbamazepine, phenytoin, or fosphenytoin therapy

 

Genotyping patients who prefer not to have venipuncture done

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

 

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR)

(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

HLAB 1502 Carbamazepine, Saliva

Aliases Lists additional common names for a test, as an aid in searching

1502
Carbamazepine Hypersensitivity
Fosphenytoin Hypersensitivity
HLA-B
HLAB 1502
LAB1502
Phenytoin Hypersensitivity
SJS
Stevens-Johnson Syndrome, Carbamazepine, Phenytoin, or Fosphenytoin
Toxic Epidermal Necrosis (TEN), Carbamazepine, Phenytoin, or Fosphenytoin